Tavapadon manufacturers
- Tavapadon
-
- $74.00 / 1mg
-
2026-04-10
- CAS:1643489-24-0
- Min. Order:
- Purity: 99.80%
- Supply Ability: 10g
|
| | Tavapadon Basic information |
| Product Name: | Tavapadon | | Synonyms: | Tavapadon;PF 6649751;CVL-751;CVL751,CVL 751,inhibit,PF 06649751,Tavapadon,Inhibitor,PF-06649751,Dopamine Receptor,PF06649751;(-)-1,5-Dimethyl-6-(2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)pyrimidine-2,4(1H,3H)-dione;1,5-dimethyl-6-[2-methyl-4-[[3-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]-2,4(1H,3H)-pyrimidinedione;Tavapadon (CVL-751);1,5-dimethyl-6-(2-methyl-4-{[3-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione | | CAS: | 1643489-24-0 | | MF: | C19H16F3N3O3 | | MW: | 391.35 | | EINECS: | | | Product Categories: | | | Mol File: | 1643489-24-0.mol |  |
| | Tavapadon Chemical Properties |
| density | 1.332±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:20): 0.05 mg/ml,Ethanol: 2 mg/ml | | pka | 9.54±0.40(Predicted) | | form | A crystalline solid | | color | White to light yellow | | InChI | InChI=1S/C19H16F3N3O3/c1-10-9-12(28-17-14(19(20,21)22)5-4-8-23-17)6-7-13(10)15-11(2)16(26)24-18(27)25(15)3/h4-9H,1-3H3,(H,24,26,27) | | InChIKey | AKQXQLUNFKDZBN-UHFFFAOYSA-N | | SMILES | CC1C=C(OC2N=CC=CC=2C(F)(F)F)C=CC=1C1N(C(=O)NC(=O)C=1C)C |
| | Tavapadon Usage And Synthesis |
| Uses | Tavapadon (PF-06649751) is an orally active and highly selective dopamine D1/D5 receptor partial agonist. Tavapadon is effective in enabling movement and reducing disability and has the potential for Parkinson's disease[1]. | | in vivo | Tavapadon (PF-06649751; 0.02 and 0.04 mg/kg; s.c.) at the 0.04 mg/kg test dose increases locomotor activity, whereas the 0.02 mg/kg dose has little or no effect[1].
Tavapadon (0.04 mg/kg, s.c.) also improves parkinsonian disability scores with the maximal improvement observed at 110 min after drug administration[1].
Higher doses of Tavapadon (0.1 and 0.15 mg/kg; s.c.) leads to statistically significant improvement relative to vehicle in locomotor activity[1].
Tavapadon (0.1 mg/kg; s.c.) has the mean maximal unbound plasma concentration of 8 nM and achieves 3 hours after compound administration in captive-bred macaques[1].
| | References | [1] Young D, et al. D1 Agonist Improved Movement of Parkinsonian Nonhuman Primates with Limited DyskinesiaSide Effects. ACS Chem Neurosci. 2020 Feb 19;11(4):560-566. DOI:10.1021/acschemneuro.9b00589 |
| | Tavapadon Preparation Products And Raw materials |
|